Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Income (2016 - 2025)

Tg Therapeutics has reported Net Income over the past 10 years, most recently at -$84.7 million for Q4 2025.

  • Quarterly results put Net Income at -$84.7 million for Q4 2025, down 449.72% from a year ago — trailing twelve months through Dec 2025 was $339.5 million (up 1300.11% YoY), and the annual figure for FY2025 was $339.4 million, up 1299.23%.
  • Net Income for Q4 2025 was -$84.7 million at Tg Therapeutics, down from $390.9 million in the prior quarter.
  • Over the last five years, Net Income for TGTX hit a ceiling of $390.9 million in Q3 2025 and a floor of -$94.0 million in Q4 2021.
  • Median Net Income over the past 5 years was -$37.9 million (2022), compared with a mean of -$10.1 million.
  • Peak annual rise in Net Income hit 10005.87% in 2025, while the deepest fall reached 449.72% in 2025.
  • Tg Therapeutics' Net Income stood at -$94.0 million in 2021, then rose by 14.49% to -$80.4 million in 2022, then skyrocketed by 82.07% to -$14.4 million in 2023, then skyrocketed by 267.92% to $24.2 million in 2024, then tumbled by 449.72% to -$84.7 million in 2025.
  • The last three reported values for Net Income were -$84.7 million (Q4 2025), $390.9 million (Q3 2025), and $28.2 million (Q2 2025) per Business Quant data.